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Abstract: Zolendronic acid is a nitrogenous biphosphonate commonly used as an 
  intravenous infusion for the management of Paget’s disease, osteoporosis, and hypercalce-
mia of   malignancy. We report a rare and challenging complication of zolendronate infusion: 
unilateral acute anterior uveitis followed by persistently raised intraocular pressure despite 
being on four different classes of antiglaucoma medication. The challenge was that the 
patient required topical steroid to treat her uveitis in the background of known glaucoma 
with corresponding steroid response. She eventually underwent a left phacotrabeculectomy 
augmented with 5-fluorouracil. Four weeks postoperatively she developed an encapsulated 
bleb and underwent needling with 5-fluorouracil. This case highlights the importance of 
having a high index of suspicion for anterior uveitis in patients with a red and painful eye 
after initiating biphosphonate therapy. Caution should also be exercised when prescribing 
biphosponates to glaucoma patients.
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Introduction
Zolendronic acid is a nitrogenous biphosphonate commonly used as an intravenous 
infusion for the management of Paget’s disease,1 osteoporosis prophylaxis,2 and treat-
ment of hypercalcemia of malignancy.3 Uveitis is an uncommon ocular complication 
of zolendronate. The HORIZON (Health Outcomes and Reduced Incidence with 
  Zoledronic Acid Once Yearly)4 trial in postmenopausal women with osteoporosis 
showed an absolute increase of only 0.69% in inflammatory ocular adverse events, 
mainly conjunctivitis, during the first 15 days after infusion in comparison with con-
trols, but no case of uveitis.4
Nevertheless, a small number of studies have reported acute anterior uveitis 
  following biphosphonate infusion, including zolendronate.5–7 The onset of symptoms 
in most cases is within 72 hours of starting therapy. The majority of cases resolve 
without sequelae with the administration of topical treatment and cessation of the 
bisphosphonate. However, in our case the acute anterior uveitis was associated with 
persistently raised intraocular pressure (IOP) despite maximum topical antiglaucoma-
tous treatment, leading to glaucoma filtration surgery and subsequently needling with 
5-fluorouracil. To the best of our knowledge this is the first case of this kind to be 
reported and highlights this rare, and potentially sight threatening, complication of 
zolendronate infusion.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1148
Khan et al
Case presentation
This interventional case report describes a 69-year-
old   Caucasian lady, on adjuvant letrozole for hormone 
  responsive breast adenocarcinoma, who was also started 
on the   biphosphonate zolendronate, as prophylaxis against 
  osteoporosis. Within 48 hours of receiving her first zolen-
dronate infusion she developed a red and painful photophobic 
left eye. She was diagnosed with severe anterior uveitis with 
corneal edema and plus three cells with a secondary rise in the 
IOP to 40 mmHg. She had a past history of left episcleritis 
and had been diagnosed with primary open angle glaucoma 
11 years earlier with advanced cupping bilaterally. She had 
already had glaucoma surgery in her right eye and was known 
to be a steroid responder.
During follow-up, IOP remained high in the left eye 
over a 4-month period, fluctuating between 26 mmHg and 
42 mmHg, despite being on four antiglaucoma   medications 
(latanoprost, Cosopt®, acetazolomide 250 mg twice daily). 
The challenge was that she required topical steroid (Pred 
Forte®) drops to treat her uveitis in the background of 
known glaucoma and steroid response. A previous episode 
of postoperative uveitis in the fellow eye demonstrated she 
could not be controlled effectively with weaker steroid 
(rimexolone). In this context, stronger steroids were used 
to control the inflammation. The persistently raised IOP 
resulted in early visual field loss and she underwent a left 
  phacotrabeculectomy with 5-fluorouracil (25 mg/mL). This 
lady’s severe uveitis was maximally controlled by Pred Forte. 
Given that her presenting pressure was 40 mmHg, her raised 
IOP was in part due to inflammation. Therefore, treating the 
uveitis was the immediate concern. The balance was control-
ling the inflammation so that we could speedily carry out 
glaucoma surgery, versus tolerating a spell of high pressure 
(largely controlled by antiglaucoma medication).
With a previous history of uveitis, not surprisingly, 
4 weeks postoperative she developed an encapsulated bleb 
with an IOP of 51 mmHg and underwent needling with 
5-  fluorouracil. Four weeks post-needling, an injected diffuse 
bleb was noted with persistently raised IOP (26–33 mmHg), 
with an element of steroid response. Her visual acuity 
remained stable at 6/6. Eventually IOP was controlled at 
17 mmHg with no topical medication, careful postopera-
tive follow-up, bleb massage, and cessation for the need for 
topical steroids.
Discussion
The use of bisphosphonates is indicated in osteoporosis, 
bony metastases with hypercalcemia, and Paget’s disease 
due to their ability to inhibit osteoclastic activity and bone 
resorption. Biphosphonates have great affinity for calcium 
and therefore preferentially accumulate in the bone.   Common 
side effects from bisphosphonates include dysphasia, 
influenza-like symptoms, myalgia, and arthralgia. Ocular 
complications include nonspecific conjunctivitis, episcleritis, 
scleritis, uveitis, and optic neuritis.8–10 Interestingly, acute 
anterior uveitis is more common in biphosphonates contain-
ing nitrogen (alendronate, pamidronate, zoledronate, rise-
dronate), although in one report uveitis has been associated 
with biphosphonates not containing nitrogen (clodronate, 
etidronate).11 The inflammatory mechanism remains unclear, 
but may be related in part to higher levels of proinflammatory 
cytokines (interleukin-6 and tumor necrosis factor-alpha) 
caused by biphosphonates.12
On resolution of the initial uveitic episode, various 
  management options have been attempted. Some patients 
have been switched to a different drug of the same class, 
with some observing decreased inflammation and some 
not noticing any relapse at all, suggesting immunological 
  tolerance.13 Recurrence of ocular inflammation has also been 
shown to occur on rechallenge with the same drug,14 and it has 
been suggested that the offending drug should be   discontinued 
in order to prevent involvement of the   contralateral eye and 
recurrent or chronic ocular inflammation. Patients who are 
susceptible to nitrogen-containing biphosphonates should be 
switched to the non-nitrogen-containing bisphosphonates. 
The safety of repeating the infusions of zoledronic acid in 
these patients, even with prophylactic topical steroids and 
atropine, has not been established.
Conclusion
In summary, the indications for bisphosphonates are clear 
and their benefits proven. Our case serves to illustrate a 
rare complication of anterior uveitis following treatment 
in a patient with a known history of glaucoma and eye 
surgery. The management was challenging, but successful. 
Had the acute anterior uveitis presented in the right eye 
with a previous trabeculectomy, the management would 
have been more complicated and sight threatening. This 
rare case emphasizes the importance of exercising caution 
when prescribing biphosponates to glaucoma patients. 
A high index of suspicion is needed in patients with a red 
and painful eye for anterior uveitis after initiating biphos-
phonate therapy.
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